High-dose vitamin D was associated with stronger cognition in a high-risk older cohort
In older adults already showing mild cognitive impairment and sleep disturbance, vitamin D intake of at least 5,000 IU a day was associated with better performance on a standard cognitive screening test. The finding points to a potentially modifiable exposure during a period when the brain may still be responsive to intervention.
The study included 54 adults with both mild cognitive impairment and sleep problems, a combination that places patients closer to the dementia trajectory than healthy aging alone. Those who reported taking at least 5,000 IU of vitamin D daily scored more than 13% higher on the Montreal Cognitive Assessment, or MoCA, than participants who took none, even after adjustment for other factors. Lower daily doses did not show the same association.
The association was strongest at 5,000 IU or more
The dose pattern matters because it suggests the signal was not simply tied to any supplementation at all. In this cohort, only the highest intake category separated from the no-supplement group on cognitive testing, while smaller daily amounts did not track with improved scores. For clinicians, that raises a basic question at the bedside: if vitamin D is relevant here, is the effect threshold-dependent rather than incremental?
MoCA is widely used to screen memory, attention, language, executive function, and other domains affected early in dementia. A difference of more than 13% on that test is not a trivial numerical shift in a group already experiencing cognitive vulnerability. Sleep disruption and early cognitive decline often travel together, and the combination may expose a window in which brain function is still flexible enough to respond to systemic factors such as nutritional status.
Sleep disruption may amplify early neurocognitive vulnerability
Sleep is not a passive background variable in dementia risk. In Alzheimer’s disease, disrupted sleep can worsen cognition, while cognitive decline can further damage sleep architecture, producing a reinforcing loop that is difficult to break. Half of people with moderate to severe Alzheimer’s disease report sleep disturbances, which makes sleep quality more than a symptom issue; it may be part of the disease biology itself.
Vitamin D has biologic roles that make the association plausible, even if causality remains unproven. The nutrient is involved in muscle and nerve function, and it has been linked to sleep quality and sleep-wake regulation. Vitamin D deficiency has also been associated in prior work with insomnia and more frequent nighttime awakenings. In a cohort already showing both sleep disturbance and cognitive impairment, that convergence creates a reasonable hypothesis: correcting a deficiency or augmenting intake may support the systems that preserve attention and memory.
D2 and D3 looked similar in this analysis
The form of vitamin D did not appear to change the cognitive pattern. Participants using vitamin D2, commonly obtained from plants or fungi, performed similarly to those taking vitamin D3, the form synthesized in skin after sun exposure and also found in animal-based foods. The study did not identify a cognitive advantage for one formulation over the other.
That finding is clinically useful because it suggests the observed association may be related to vitamin D exposure itself rather than a unique property of a single formulation. At the same time, the result should not be overread. A small observational sample cannot establish that vitamin D improved cognition, only that higher self-reported intake tracked with higher MoCA scores in this specific group.
The cohort represents an early window, not established dementia
The participants were not described as having diagnosed Alzheimer’s disease. They had mild cognitive impairment, an intermediate stage between normal age-related cognitive change and dementia. That distinction is central. Interventions aimed at this stage are often more biologically plausible than treatment once neurodegeneration is advanced, because there may still be enough preserved circuitry for supportive measures to matter.
Victoria Pak, the senior author, described the overlap of sleep disturbance and mild cognitive impairment as a possible critical window for intervention, when cognitive changes are emerging but opportunities to support brain health may remain. The framing fits the clinical problem. Once dementia is established, reversal is rare; earlier stages are where prevention-oriented strategies have the best chance of affecting the trajectory.
Still, the dataset is preliminary. A sample of 54 adults is too small to settle dose, duration, safety, or efficacy questions. The study design also leaves open the possibility that people taking higher doses of vitamin D differed in other ways that influence cognition, such as diet, overall health behavior, or prior recognition of deficiency. No randomized comparison can be built from these data.
What the finding can and cannot support in practice
The result does not justify telling all older adults with sleep problems to start high-dose vitamin D in hopes of improving memory. It does justify more careful study of vitamin D as a potentially modifiable factor in people with early cognitive decline, especially when sleep disturbance is already present. The clinical value lies in the combination of accessibility, biologic plausibility, and the fact that the signal emerged in a group at elevated dementia risk.
The study was published in Sleep Medicine and funded by the National Institute on Aging through R01AG097853-01 and R61AG080606. Emory investigators Sirui Zhou, Paul Sudeshna, Lynn Marie Trotti, Donald Bliwise, and Victoria Pak contributed to the report. For now, the most defensible reading is narrow: in a small group of older adults with mild cognitive impairment and sleep disturbance, higher reported vitamin D intake aligned with better cognitive screening scores, while lower doses did not.
The next step is not broad supplementation advice. It is a randomized trial that can determine whether the association survives when dose, duration, baseline vitamin D status, and cognitive change are tested prospectively.